Trial Profile

Phase I study of ILP100 for wound care in healthy volunteers: Multiple and single ascending dose study

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emilimogene sigulactibac (Primary)
Indications Wounds
Focus Adverse reactions; First in man
Acronyms SITU-SAFE

Most Recent Events

06 Jun 2023 According to an Ilya Pharma media release, first randomized controlled trial with ILP100 (INN emilommigene sigulactibact) published in The Lancet Discovery Sciences Journal eClinical Medicine (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00191-8/fulltext)
07 Jan 2021 Results presented in an Ilya Pharma Media Release.
13 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com